Revolutions stories

European Medicines Agency Fast-Tracks Review of Revolution Medicines' Experimental Pancreatic Cancer Pill

The EMA has granted accelerated assessment to Revolutions' experimental pancreatic cancer drug, potentially shortening the review timeline for this treatment targeting a disease with limited therapeutic options.